Skip to main content
NEKTAR THERAPEUTICS logo

NEKTAR THERAPEUTICS — Investor Relations & Filings

Ticker · NKTR ISIN · US6402681083 LEI · 5299005I24806IOIYE03 US Manufacturing
Filings indexed 1,236 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country US United States of America
Listing US NKTR

About NEKTAR THERAPEUTICS

https://www.nektar.com/

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for autoimmune and inflammatory conditions. The company's research centers on modulating the immune system to resolve imbalances and restore homeostasis. By leveraging its expertise in immune pathways, Nektar aims to develop first-in-class, disease-modifying therapies that address the root causes of immune dysfunction. Its pipeline includes investigational candidates such as rezpegaldesleukin, a therapy designed to stimulate regulatory T cells for the treatment of conditions like severe alopecia areata.

Recent filings

Filing Released Lang Actions
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
Regulatory Filings
2026-05-08 English
ARS
Annual Report
2026-04-24 English
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
Regulatory Filings
2026-04-23 English
424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
Prospectus
2026-04-23 English
424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
Prospectus
2026-04-20 English
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
Regulatory Filings
2026-04-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.